Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party on Leukaemia in Adults.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001215:Asparaginase / Q000627:therapeutic use*; D001792:Blood Platelets; D002648:Child; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000150:complications
D003561:Cytarabine; D015122:Mercaptopurine; D001215:Asparaginase; D013866:Thioguanine; D011241:Prednisone; D003630:Daunorubicin